#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Acute Toxicity of High Dose Interstitial Brachytherapy Boost in Prostate Cancer


Authors: R. Soumarová;  L. Homola;  M. Štursa 1;  H. Perková
Authors‘ workplace: Onkologické centrum J. G. Mendela, Nový Jičín ;  Urologické oddělení nemocnice Nový Jičín 1
Published in: Čas. Lék. čes. 2006; 145: 43-49
Category: Original Article

Overview

Background.
Over the past few years, brachytherapy has become more and more common in the treatment of prostate cancer. Part of the reason behind this growth in the use of brachytherapy for the treatment of organ-confined prostate cancer is the reduced amount of acute and chronic side effects. On the other hand, brachytherapy allows for dose escalation, resulting in significant improvements in the treatment results. 

Method and Results.
From August 2004 to June 2005, we irradiated 40 patients with T1c-T3a prostate cancer. All of the patients underwent transperineal transrectal guided high dose rate (HDR) brachytherapy (two fractions, 8 Gy per fraction) and course of external beam radiotherapy with a median dose of 45–50.4 Gy. The patients were classified into three groups: low risk of recurrence (11 patients – 27.5 %), medium risk (14 patients – 35 %) and high risk (15 patients – 37.5 %). The medium age of the patients was 68.7 years (range of between 55 and 77). Hormonal treatment was carried out with 17 of the patients (42.5 %). We evaluated the quality of each implantation, including the maximum urethral and rectal dose. The calculated doses were compared with measurements by in vivo dosimetry. Acute toxicity was evaluated in all of the patients according to the Radiation Therapy Oncology Group (RTOG) scale. Each of the patients completed an International Prostatic Symptom Score (IPSS) questionnaire. Acute genitourinary morbidity grade 1 was recorded in 37.5 % of patients, and grade 2 in 15 % of patients. Urine retention in one of the patients resulted in the need to perform an epicystostomy. According to the IPSS score, the majority of patients (90 %) experienced an improvement in symptoms related to quality of life. Grade 1 acute gastrointestinal toxicity was recorded in 40 % of the patients. Grades 2-4 were not recorded. 

Conclusions.
We showed that the combination of external beam radiotherapy and HDR brachytherapy in the treatment of early prostate cancer to be feasible and well tolerated. Acute toxicity was low and scarcely influenced the quality of life. Among the risk factors of genitourinary toxicity was the volume of the prostate. For gastrointestinal toxicity, risk factors included a combination of HDR brachytherapy and external beam radiotherapy to the pelvis, as well as hormonal treatment. 

Key words:
high dose rate brachytherapy, organ-confined prostate cancer, acute toxicity.


Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental Hygienist

Article was published in

Journal of Czech Physicians


Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#